Sankaijo Tablet
NDC Package 49873-404-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Sankaijo (docusate sodium, sennosides) tablets is uses■for the relief of occasional constipation (irregularity) ■generally produces bowel movement in 6 to 12 hours. This formulation utilizes a tablet delivery system. Marketed by Sato Pharmaceutical Co., Ltd., this product is identified by NDC 49873-404 and is authorized under FDA application M007.

Identification & Billing

NDC Package Code
49873-404-01
Package Description
1 BOTTLE in 1 CARTON / 150 TABLET in 1 BOTTLE
Product Code
49873-404
11-Digit Billing Format
49873040401
RxNorm Crosswalk
  • RxCUI: 1235252 - docusate sodium 8.33 MG / sennosides 1.36 MG Oral Tablet
  • RxCUI: 1235252 - docusate sodium 8.33 MG / sennosides, USP 1.36 MG Oral Tablet
  • RxCUI: 1235252 - DOSS Sodium 8.33 MG / sennosides, USP 1.36 MG Oral Tablet

Clinical Specifications

Proprietary Name
Sankaijo
Non-Proprietary Name
Docusate Sodium, Sennosides
Substance Name
Docusate Sodium; Sennosides
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Uses■for the relief of occasional constipation (irregularity) ■generally produces bowel movement in 6 to 12 hours

Regulatory & Marketing

Labeler Name
Sato Pharmaceutical Co., Ltd.
Product Type
Human Otc Drug
FDA Application #
M007
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
12-20-2002
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49873-404-01 identifies a specific commercial package of 1 bottle in 1 carton / 150 tablet in 1 bottle of Sankaijo, a human over the counter drug labeled by Sato Pharmaceutical Co., Ltd.. This tablet is formulated for oral use and contains docusate sodium; sennosides as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sato Pharmaceutical Co., Ltd. on December 20, 2002. The current certification is valid through December 31, 2026.

How is this Sato Pharmaceutical Co., Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49873040401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49873-404-01
11-Digit CMS (5-4-2)
49873-0404-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.